Update: NeoGenomics Shares Rise After RaDaR ST Assay Gets Expanded Medicare Coverage

03:10 PM EDT, 08/27/2026 (MT Newswires) -- (Updates with the company's latest stock move in the headline and the first paragraph.) NeoGenomics (NEO) shares were up 9% in Thursday trading after the company said its RaDaR ST molecular residual disease assay received expanded Medicare coverage to include immunotherapy response monitoring for patients with late-stage solid tumors. The determination from the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program is the third Medicare-covered indication for RaDaR ST, NeoGenomics said Wednesday in a statement. The coverage allows use of the assay to monitor response to immune-checkpoint inhibitor therapy, and NeoGenomics said it has two additional RaDaR ST submissions pending. Price: 18.93, Change: +1.56, Percent Change: +8.95